Crenezumab doses of ≤120 mg/kg intravenously q4w were well tolerated. 1 key finding →
Design: open-label trial Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients. 1 key finding →
Design: open-label trial Participants: 2,042 Evidence: high
Full summary, score breakdown and related studies → Original source
Methylthioninium (MT) is a tau aggregation inhibitor with therapeutic potential in Alzheimer's disease (AD). 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
62/100
A lower incidence of dementia in bipolar patients treated with lithium has been described. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Prior qualitative literature reviews about the use of neuroleptics in dementia suggest that they are "modestly effective" in treating agitation and that no single neuroleptic is better than another. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study provides the first active comparator data on amyloid plaque clearance in patients with early symptomatic AD. 2 key findings →
Design: clinical trial Participants: 148 Evidence: high
Full summary, score breakdown and related studies → Original source
Highlights Brexpiprazole treatment for 10 weeks improved agitation in Alzheimer's dementia. 2 key findings →
Design: phase-3-trial Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Neither targeted lecanemab treatment nor treatment unrestricted by APOE ε4 genotype is cost-effective vs SoC alone for patients with MCI or mild dementia due to AD. 2 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The use of conventional anti-dementia drugs is associated with a lower mortality in nursing home residents with dementia and should be widely used in this population. 4 key findings →
Design: cohort Participants: 25,358 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
61/100
The single nucleotide polymorphism rs1080985 in the CYP2D6 gene may influence the clinical efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD). 3 key findings →
Design: cohort study Participants: 115 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD. 5 key findings →
Participants: 474 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In 1996, Kanowski et al. reported about the beneficial effects of ginkgo biloba special extract EGb 761 (240 mg/day) in outpatients with pre-senile and senile primary degenerative dementia of the Alzheimer type (DAT) and multi-infarct dementia (MID) of mild to moderate severity. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Short-term administration of latrepirdine is well tolerated in patients with HD and may have a beneficial effect on cognition. 3 key findings →
Participants: 46 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
61/100
Tacrine stabilizes or improves specific behavioral deficits and symptoms in AD. 1 key finding →
Participants: 181 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Reduction of verbal repetition was set as a treatment goal in 44% (n = 57) of randomized patients. 3 key findings →
Participants: 57 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Bapineuzumab SC once-monthly did not demonstrate significant treatment difference over placebo on cerebral amyloid signal at one year but was well-tolerated. 3 key findings →
Participants: 146 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Choline alfoscerate exhibits additional cognitive improvement in both cognitive and noncognitive domains, supporting the findings of the ASCOMALVA trial. 2 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The current study is a controlled clinical investigation of two nonpharmacological treatments of depression in patients with Alzheimer's disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, females exhibited higher tau compared with age-matched males, particularly in the setting of elevated Aβ. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although dopamine replacement therapy remains a core component of Parkinson's disease treatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical and surgical approaches from a multidisciplinary team, and important new approaches in the delivery of dopamine replacement are becoming available. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease that is characterized by motor neuron loss and that leads to paralysis and death 2-5 years after disease onset. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. 4 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD). 4 key findings →
Participants: 72 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The 59 recruiting sites for the Alzheimer's Disease Neuroimaging Initiative (ADNI). 4 key findings →
Design: cohort study Participants: 177 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the most prevalent cause of dementia 1 . 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 3,071 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Drug repurposing for Alzheimer's disease and other neurodegenerative disorders
- Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease
- Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research
- Targeting microglia for the treatment of Alzheimer's Disease
- Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity
- Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle
- Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease
- Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis
- Psychiatric complications of treatment with corticosteroids: review with case report
- Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer's Disease
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →